SOUTH SAN FRANCISCO, Calif., Feb. 09, 2017 -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its fourth quarter and full year 2016 financial results on Thursday, February 23, 2017 after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, February 23, 2017 at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company's financial results and provide a general business update.
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 60580589.
The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
Company Contact: Heather Rowe Investor Relations 415-365-5737 [email protected]


Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 



